Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + paclitaxel for 8 cycles versus carboplatin + paclitaxel for 4 cycles followed by carboplatin alone in advanced ovarian cancer
ACTRN12610000309088Phase 3Completed
- Sponsor
- HeCOG
- Start
- Apr 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and carboplatin in ovarian cancer (2 arms), sponsored by HeCOG. Primary endpoint: Overall survival. Started Apr 2005; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ACTRN12610000309088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000309088.